Question 1 of 26

(demo test)

The one advantage an orally disintegrating tablet reliably delivers is that it can be taken anywhere, the moment the attack declares itself, without water. The wafer dissolves on the tongue and is swallowed with saliva, so the patient in a meeting or on a train need not find a glass of water first. That matters because triptan efficacy is time-dependent: the earlier in the attack the drug is taken, the higher the pain-free rate. It also suits patients who cannot swallow pills and those whose nausea makes drinking unappealing. Convenience, not pharmacokinetics, is the gain, which makes option C correct.

The pharmacology explains why the other claims fail. Although the tablet disintegrates in the mouth, the drug is not absorbed across the buccal mucosa; it is swallowed and absorbed from the gastrointestinal tract exactly like the conventional tablet, so time to peak concentration and time to onset are no faster. Rizatriptan and zolmitriptan wafers are supplied at the same strengths as their conventional counterparts. Bradley makes the limiting point explicitly: once an attack is fully developed, oral preparations are almost always less effective because of decreased gastrointestinal motility and poor absorption, and if severe nausea or vomiting develops a non-oral route is often necessary. An orally disintegrating tablet inherits that limitation in full, because it still depends on the gut. When speed or bypass of the stomach is required, the answer is subcutaneous sumatriptan, an intranasal triptan, or metoclopramide to restore gastric emptying.

The transferable principle is that a change in dosage form alters convenience and adherence, not pharmacology: unless the route of absorption changes, onset, dose and receptor-mediated adverse effects all stay the same. This sits at the Intermediate level of RITE content, because it asks the resident to separate a marketing formulation claim from a real pharmacokinetic advantage.

Incorrect Answers

• A. Rizatriptan and zolmitriptan orally disintegrating tablets contain the same milligram strengths as their standard tablets. Choose this if the question had asked about a formulation that truly delivers more drug to the receptor, such as 6 mg subcutaneous sumatriptan.
• B. The wafer dissolves in saliva but is swallowed; there is no meaningful transmucosal absorption and no faster onset. Choose this if the item concerned a non-oral product such as sumatriptan nasal spray or intranasal zolmitriptan.
• D. Coronary vasoconstriction is a 5-HT1B property of the molecule itself, identical whichever oral form is used, and the same contraindications apply. Choose this if the question asked which acute agent avoids vasoconstriction, such as lasmiditan or a gepant.
• E. Medication overuse headache depends on how many days a month an acute drug is taken, not on dosage form; triptans carry moderate risk. Choose this if the question asked which acute class carries the lowest overuse risk, where the answer is NSAIDs.

Testing Pearls

• Orally disintegrating triptans dissolve on the tongue but are swallowed and absorbed from the gut, so onset is no faster than a conventional tablet.
• Rizatriptan and zolmitriptan wafers come in the same strengths as standard tablets.
• Treating early beats changing formulation; when vomiting or gastroparesis dominates, switch to a subcutaneous or intranasal triptan.
• Medication overuse headache risk ranks opioids and butalbital highest, triptans intermediate and NSAIDs lowest, and follows treatment days per month.

References

1. Jankovic J, Mazziotta JC, Newman NJ, Pomeroy SL, editors. Bradley and Daroff’s Neurology in Clinical Practice. 8th ed. Philadelphia, PA: Elsevier; 2022. p. 1756, 1762-1763.
2. Gladstone JP, Gawel M. Newer formulations of the triptans: advances in migraine management. Drugs. 2003;63(21):2285-305.
3. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22(8):633-58.